Chloroquine + Primaquine — Competitive Intelligence Brief

Chloroquine + Primaquine (Chloroquine + Primaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium parasite heme metabolism and mitochondrial function Infectious Disease Small molecule

Target snapshot

Chloroquine + Primaquine (Chloroquine + Primaquine) — U.S. Army Medical Research and Development Command. Chloroquine and primaquine work together as antimalarial agents by interfering with parasite DNA and disrupting the parasite's ability to metabolize hemoglobin.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Chloroquine + Primaquine TARGET	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
chlorproguanil-dapsone plus artesunate	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
Artemether + Lumefantrine	Artemether + Lumefantrine	GlaxoSmithKline	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and heme detoxification pathway
artesunate-amodiaquine (AS-AQ)	artesunate-amodiaquine (AS-AQ)	Yale University	marketed	Artemisinin derivative + aminoquinoline antimalarial combination	Plasmodium falciparum heme iron (Fe2+), parasite DNA, heme polymerase
artemether-lumefantrine (ALN)	artemether-lumefantrine (ALN)	Jhpiego	marketed	Antimalarial combination	Plasmodium falciparum heme metabolism and parasite membranes
Artemether-lumefantrine combination plus albendazole	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class